🇺🇸 FDA
Patent

US 10301393

Methods of treating multiple sclerosis using anti-CD20 antibodies

granted A61KA61K2039/505A61K39/39541

Quick answer

US patent 10301393 (Methods of treating multiple sclerosis using anti-CD20 antibodies) held by VACCINEX, INC. expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K39/39541, A61K39/39558, A61P